


# Life Sciences DISCOVERY FUND NOW

www.lsdfa.org

## Innovative Stroke Treatment Shows Promise

Consisting of a combination of catheter-delivered ultrasound and a clot-busting drug, this new therapy is showing encouraging results

Intracranial hemorrhage is a devastating form of stroke. Half of all patients die within one month of the event, and those who survive typically suffer dramatic loss of brain function and motor skills. Often, they are unable to resume normal activities such as caring for themselves, placing a stressful burden on family members or requiring more extensive—and expensive—ongoing care. The more quickly a clot can be removed the better, and hours count.



Recognizing this challenge, the Life Sciences Discovery Fund provided a \$170,000 grant which allowed David Newell, of the Swedish Neuroscience Institute, to team up with Bothell-based EKOS Corporation in evaluating an

innovative new stroke treatment. Consisting of a combination of catheter-delivered ultrasound and a clot-busting drug, this new therapy is showing promising results in the race to remove clots.

Just ask one of the clinical trial participants.

A Tacoma-area police officer suffered a stroke and his prognosis using conventional therapies was poor. But a lucky chain of events and swift action by the officer's girlfriend resulted in almost immediate treatment with the innovative catheter. He returned to work rather than likely progressing to a coma leading to death.

This work has the potential to save lives in Washington and across the nation, allowing stroke survivors to return home and to resume their daily lives and normal activities more quickly than ever before. The work is exciting enough to have been accepted for presentation at an important international stroke conference.

And EKOS Corporation, which has been working with Dr. Newell since 2007, is well positioned to ensure that the economic benefits of this breakthrough therapy accrue in Washington.